Clinical Trial Update: Efficacy and Safety of Cadonilimab Plus Anlotinib in Advanced STS That Failed the Previous First-line Standard Treatment [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Cadonilimab plus Anlotinib in advanced soft tissue sarcoma after failure of first-line therapy. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Anlotinib (anlotinib)
• Cadonilimab

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Soft Tissue Sarcoma | Phase 2 | Status: RECRUITING